Coagulation disorders in cirrhosis;Trastornos de coagulación en el cirrótico

Revista de Investigacion Clinica

Volumn 59, Issue 2, 2007, Pages 153-160

  Téllez Ávila, Felix I ^a   Chávez Tapia, Norberto C ^a   Torre Delgadillo, Aldo ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Cirrhosis; Coagulation

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; HEPARIN; HEPARIN COFACTOR II; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PREKALLIKREIN; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ARTICLE; BLOOD CLOTTING DISORDER; DISSEMINATED INTRAVASCULAR CLOTTING; DYSFIBRINOGENEMIA; FIBRIN FORMATION; FIBRINOGEN SYNTHESIS; FIBRINOLYSIS; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION; MESENTERIC VEIN THROMBOSIS; PORTAL VEIN THROMBOSIS; THROMBOCYTE ANOMALY; VITAMIN K DEFICIENCY;

AFIBRINOGENEMIA; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; BLOOD PLATELETS; DISSEMINATED INTRAVASCULAR COAGULATION; FIBRINOLYSIS; HEMORRHAGIC DISORDERS; HUMANS; LIVER CIRRHOSIS; MESENTERIC VEINS; PORTAL VEIN; THROMBOPHILIA; THROMBOPOIETIN; THROMBOSIS; VITAMIN K DEFICIENCY;

EID: 34447292379     PISSN: 00348376     EISSN: 00348376     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Tripodi A, Salermo F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, Manucci PM. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41(3): 553-8.
2. Mannucci PM. Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No. J Thromb Haemost 2006; 4(4): 721-3.
3. Reverter JC. Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? Yes. J Thromb Haemost 2006; 4(4): 717-20.
4. Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Gastroenterology 2000; 95(10): 2936-9.
5. Karasu Z, Gurakar A, Kerwin B, et al. Effect of transjugular intrahepatic portosystemic shunt on thrombocytopenia associated with cirrhosis. Dig Dis Sci 2000; 45(10): 1971-6.
6. Palsson B, Verbaan H. Partial splenic embolization as pretreatment for antiviral therapy in hepatitis C virus infection. Eur J Gastroenterol Hepatol 2005; 17(11): 1153-5.
7. Foruny JR, Blazquez J, Moreno A, Bercena A, et al. Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization. Eur J Gastroenterol Hepatol 2005; 17(11): 1157-64.
8. Kawasaki T, Takeshita A, Souda K, et al. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. Am J Gastroenterol 1999; 94(7): 1918-22.
9. Peckradosavljevic M, Wichlas M, Zacherl J, et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 2000; 95(3): 795-801.
10. Yagura M, Tanaka A, Tokita H, Kamitsukasa H, Harada H. Factors regarding increase of platelet counts in chronic hepatitis C patients with sustained virological response to interferon-Relation to serum thrombopoietin levels. Hepatol Res 2005; 33(3): 211-5.
11. Rios R, Sangro B, Herrero I, Quiroga J, Prieto J. The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am J Gastroenterol 2005; 100(6): 1311-16.
12. Samuel H, Nardi M, Karpatkin M, Hart D, Belmont M, Karpatkin S. Differentiation of autoimmune thrombocytopenia from thrombocytopenia associated with immune complex disease: systemic lupus erythematosus, hepatitis-cirrhosis, and HIV-1 infection by platelet and serum immunological measurements. Br J Haematol 1999; 105(4): 1086-91.
13. Peltz S. Severe thrombocytopenia secondary to alcohol use. Postgrad Med 1991; 89(6): 75-6, 85.
14. Latvala J, Parkkila S, Niemela O. Excess alcohol consumption is common in patients with cytopenia: Studies in blood and bone marrow cells. Alcohol Clin Exp Res 2004; 28(4): 619-24.
15. O'Grady JG, Alexander GJM, Hayllat KM, et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97: 439-45.
16. Bismuth H, Samuel D, Castaing D, et al. Orthotopic liver transplantation and subfulminant hepatitis. The Paul Brousse experience. Ann Surg 1995; 222: 109-19.
17. Paramo JA, Rocha E. Hemostasis in advanced liver disease. Semin Thromb Hemost 1993; 19: 184-90.
18. Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
19. Forman LM, Lucey MR. Predicting the prognosis of chronic liver disease: an evolution from child to MELD. Mayo end-stage liver disease. Hepatology 2001; 33: 473-5.
20. Rovert A, Chazouilleres O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio? Hepatology 1996; 24: 1392-4.
21. Ramsey G. Treating coagulopathy in liver disease with plasma transfusions or recombinant factor VIIa: an evidence-based review. Best Pract Res Clin Haematol 2006; 19(1): 113-26.
22. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liver Dis 2002; 22(1): 83-96.
23. Northup PG, McMahon MM, Ruhl AP, Altschuler SE, Volk-Bednarz A, Caldwell SH, Berg CL. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006; 101(7): 1524-8.
24. Drin FG, Thomson JM, Dymock IW, et al. Abnormal fibrin polymerization in liver disease. Br J Haematol 1976; 34: 427-37.
25. Narvaiza MJ, Fernandez J, Cuesta B, Paramo JA, Rocha E. Role of sialic acid in acquired dysfibrinogenemia associated with liver cirrhosis. Ric Clin Lab 1986; 16(4): 563-8.
26. Van Thiel DH, George M, Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost 2001; 85: 667-70.
27. Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, Gresele P. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003; 38(1): 230-7.
28. Agarwal S, Joyner KA Jr, Swaim MW. Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease. Am J Gastroenterol 2000; 95(11): 3218-24.
29. Piscaglia F, Donati G, Giannini R, Bolondi L. Liver cirrhosis, ascites, and hyperfibrinolysis. Am J Gastroenterol 2001; 96(11): 3222.
30. Blanchard RA, Furie BC, Jorgensen M, et al. Acquired vitamin K dependent carboxylation deficiency in liver disease. N Engl J Med 1981; 305: 242-8.
31. Nakamura S, Nouso K, Sakaguchi K, Ito YM, Ohashi Y, Kobayashi Y, et al. Sensitivity and specificity of Des-Gamma-Carboxy Prothrombin for Diagnosis of Patients with Hepatocellular Carcinomas Varies According to Tumor Size. Am J Gastroenterol 2006; 101: 1-6.
32. Violi F, Ferro D, Basili S, et al. Association between low grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis. Gastroenterology 1995; 109: 531-9.
33. Ben-Ari Z, Osman E, Hutton RA, Burroughs AK. Disseminated intravascular coagulation in liver cirrhosis: fact or fiction? Am J Gastroenterol 1999; 94(10): 2977-82.
34. Joist JH. AICF and DIC in liver cirrhosis: Expressions of a hypercoagulable state. Am J Gastroenterol 1999; 94: 2801-3.
35. Northup PG, McMahon MM, Ruhl AP, Altschuler SE, Volk-Bednarz A, Caldwell SH, Berg CL. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006; 101(7): 1524-8.
36. Yerdel MA, Gunson B, Mirza D, et al. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation 2000; 69: 1873-81.
37. Erkan O, Bozdayi AM, Disibeyaz S, Oguz D, Ozcan M, Bahar K, et al. Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis. Eur J Gastroenterol Hepatol 2005; 17(3): 339-43.
38. Amitrano L, Guardascione MA, Ames PR, Margaglione M, Iannaccone L, Brancaccio V, Balzano A. Increased plasma prothrombin concentration in cirrhotic patients with portal vein thrombosis and prothrombin G20210A mutation. Thromb Haemost 2006; 95(2): 221-3.
39. Walker AP. Portal vein thrombosis: what is the role of genetics? Eur J Gastroenterol Hepatol 2005; 17(7): 705-7.
40. Everson GT. A hepatologist's perspective on the management of coagulation disorders before liver transplantation. Liver Transplant Surg 1997; 3: 646-52.
41. Youssef WI, Salazar F, Dasarathy S, Beddow T, Mullen KD. Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol 2003; 98(6): 1391-4.
42. García-Tsao G. Current management of the complication of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gatroenterology 2001; 120: 726-48.
43. MacLennan S, Williamson LM. Risks of fresh frozen plasma and platelets. J Trauma 2006; 60(6 Suppl.): S46-S50.
44. French CJ, Bellomo R, Angus P. Cryoprecipitate for the correction of coagulopathy associated with liver disease. Anaesth Intensive Care 2003; 31(4): 357-61.
45. Bernstein D. Effectiveness of the recombinant factor VIIa in patients with the coagulopathy of advanced child's B and C cirrhosis. Semin Thromb Hemost 2000; 26: 437-8.
46. Niemann CU, Behrends M, Quan D, Eilers H, Gropper MA, Roberts JP, Hirose R. Recombinant factor VIIa reduces transfusion requirements in liver transplant patients with high MELD scores. Trans Med 2006; 16(2): 93-100.
47. Gala B, Quintela J, Aguirrezabalaga J, Fernandez C, Fraguela J, Suarez F, Gomez M. Benefits of recombinant activated factor VII in complicated liver transplantation. Transplant Proc 2005; 37(9): 3919-21.
48. Jimenez-Saenz M. Recombinant factor VIIa for variceal bleeding: when, why, and how? Gastroenterology 2005; 128(4): 1150-1.
49. Pavese P, Bonadona A, Beaubien J, Labrecque P, Pernod G, Letoublon C, Barnoud D. FVIIa corrects the coagulopathy of fulminant hepatic failure but may be associated with thrombosis: a report of four cases. Can J Anaesth 2005; 52(1): 26-9.
50. Shao YF, Yang JM, Chau GY, Sinivatanauksorn Y, Zhong SX, Erhardtsen E, et al. Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Surg 2006; 191(2): 245-9.
51. Murphy MF, Wallington TB, Kelsey P, Boulton F, Bruce M, Cohen H, et al. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the clinical use of red cell transfusions. Br J Haematol 2001; 113(1): 24-31.
52. Porte RJ, Molenaar IQ, Begliomini B, et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomized double-blind study. EMSALT Study Group. Lancet 2000; 355: 1303-9.
53. Kang Y, Lewis JH, Navalgund A, et al. Epsilonaminocaproic for treatment of fibrinolysis during liver transplantation. Anesthesiology 1987; 66: 766-73.
54. Dalmau A, Sabate A, Acosta F, et al. Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation. Anesth Analg 2000; 91: 29-34.